Related Experiment Video

Updated: Jul 18, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

[Special features of pathogenesis and pharmacotherapy of chronic heart failure in women]

S N Tereshchenko, E S Atroshchenko, I V Zhirov

    Kardiologiia
    |December 13, 2006
    PubMed

    Insights

    Cardiovascular disease mortality is higher in European women. Differences in cardiac remodeling and drug responses impact heart failure prognosis and treatment effectiveness differently between sexes.

    Area of Science:

    • Cardiology
    • Sex-based differences in medicine
    • Cardiovascular diseases

    Context:

    • Cardiovascular disease mortality in Europe now exceeds that in men.
    • Cardiac remodeling processes differ significantly between women and men.
    • These sex-specific differences influence chronic heart failure prognosis.

    Purpose:

    • To investigate the sex-based differences in cardiac remodeling and chronic heart failure development post-myocardial infarction.
    • To analyze the differential efficacy and safety of pharmacotherapies in women versus men.

    Summary:

    • Women more frequently develop chronic heart failure with preserved systolic function after myocardial infarction, unlike men who predominantly experience systolic dysfunction.
    • Pharmacotherapies like thrombolysis are less effective in women.
    • Women exhibit reduced sensitivity to angiotensin-converting enzyme inhibitors and a higher incidence of complications with digoxin and certain antiarrhythmic drugs.

    Impact:

    • Highlights the need for sex-specific approaches in cardiovascular disease management.
    • Informs the development of tailored treatment strategies for heart failure in women.
    • Emphasizes the importance of considering sex as a biological variable in clinical trials and therapeutic guidelines.

    More Related Videos

    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

    Published on: February 18, 2022

    Related Concept Videos

    Pathophysiology of Heart Failure01:17

    Pathophysiology of Heart Failure

    Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure I: Introduction01:27

    Heart Failure I: Introduction

    Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
    Heart Failure VII: Nursing Interventions01:30

    Heart Failure VII: Nursing Interventions

    The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...